<DOC>
	<DOC>NCT00772603</DOC>
	<brief_summary>Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures</brief_title>
	<detailed_description>Multicenter, double-blind, randomized, placebo-controlled, three-arm. parallel-group study of the efficacy and safety of extended-release oxcarbazepine in the treatment of adults with refractory partial onset epilepsy.</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Capable of complying with the study procedures. Able to provide written informed consent Male or female aged 18 to 65 years, inclusive. Diagnosis of partial onset seizures Minimum of three seizures per 28 days Receiving treatment with 13 AEDs Refractory to at least one AED No progressive neurological conditions by recent MRI/CT Adequate birth control in women of childbearing potential Refractory to OXC for reasons of efficacy Recent status epilepticus Recent nonepileptic seizures Current diagnosis of major depression Recent suicidal plan or intent or more than one attempt Current use of oxcarbazepine, felbamate for &lt; 18 months, phenytoin with levels &gt;15mcg/mL or frequent need for rescue benzodiazepines Current use of sodiumlowering nonseizure medications. Clinically significant hepatic, renal, or cardiovascular function History of recent substance abuse Females who are pregnant or lactating. Hypersensitivity to OXC or related drugs Difficulty swallowing study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Partial onset epilepsy</keyword>
	<keyword>Partial onset seizures</keyword>
</DOC>